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ABSTRACT
Background Although generally mild, the 2009e2010
influenza A/H1N1 pandemic caused two major surges in
hospital admissions in the UK. The characteristics of
patients admitted during successive waves are
described.
Methods Data were systematically obtained on 1520
patients admitted to 75 UK hospitals between May 2009
and January 2010. Multivariable analyses identified
factors predictive of severe outcome.
Results Patients aged 5e54 years were over-
represented compared with winter seasonal admissions
for acute respiratory infection, as were non-white ethnic
groups (first wave only). In the second wave patients
were less likely to be school age than in the first wave,
but their condition was more likely to be severe on
presentation to hospital and they were more likely to
have delayed admission. Overall, 45% had comorbid
conditions, 16.5% required high dependency (level 2) or
critical (level 3) care and 5.3% died. As in 1918e1919,
the likelihood of severe outcome by age followed
a W-shaped distribution. Pre-admission antiviral drug use
decreased from 13.3% to 10% between the first and
second waves (p¼0.048), while antibiotic prescribing
increased from 13.6% to 21.6% (p<0.001). Independent
predictors of severe outcome were age 55e64 years,
chronic lung disease (non-asthma, non-chronic
obstructive pulmonary disease), neurological disease,
recorded obesity, delayed admission ($5 days after
illness onset), pneumonia, C-reactive protein $100 mg/
litre, and the need for supplemental oxygen or
intravenous fluid replacement on admission.
Conclusions There were demographic, ethnic and
clinical differences between patients admitted with
pandemic H1N1 infection and those hospitalised during
seasonal influenza activity. Despite national policies
favouring use of antiviral drugs, few patients received
these before admission and many were given antibiotics.
INTRODUCTION
On 11 June 2009, WHO announced an inﬂuenza
pandemic after a novel strain of inﬂuenza A virus
emerged and spread worldwide.1 2 In the UK the
Inﬂuenza Clinical Information Network (FLU-CIN)
was established in May 2009 to undertake clinical
surveillance of hospitalised cases.3 Having already
documented the ﬁrst wave of the pandemic
(MayeSeptember 2009),3 this paper presents an
analysis across the ﬁrst and second pandemic
waves.
METHODS
As previously described,3 trained FLU-CIN staff
extracted demographic and clinical data from
hospital case notes and electronic records. Patients
with pandemic inﬂuenza A/H1N1 2009 infection
(‘pandemic H1N1’) conﬁrmed by real-time reverse
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transcribed PCR were included; no other selection criteria were
applied. FLU-CIN was an ‘emergency’ initiative with a purpo-
sive sampling frame based on 13 sentinel hospitals situated in
ﬁve clinical ‘hubs’ in Nottingham, Leicester, London, Shefﬁeld
and Liverpool, with contributions from a further 45 non-sentinel
hospitals in England and 17 in Scotland, Wales and Northern
Ireland. This included ﬁve children’s hospitals and ﬁve tertiary
respiratory referral centres (three with facilities for Extra
Corporeal Membrane Oxygenation).i Participating hospitals
were requested to notify all cases of conﬁrmed pandemic H1N1
infection.
Descriptive analyses considered demographic data, pre-
existing comorbidities recorded in case notes, pregnancy,
physician-deﬁned obesity, clinical parameters and clinical
management details. Paediatric data were described as abnormal
when values lay outside two standard deviations of normal
ranges for respiratory rate, heart rate and blood pressure,
adjusting for age, sex and temperature (heart rate only).3 4 We
examined total and weighted comorbidity burden (the latter
using Charlson’s comorbidity index).5 6
Using logistic regression (Wald tests) we investigated differ-
ences by pandemic wave and identiﬁed risk factors for severe
outcomes. The split between ﬁrst and second waves was deﬁned
using national surveillance data (ﬁrst wave: to 31 August 2009;
second wave: from 1 September 2009).7 ‘Severe outcome’ was
deﬁned as admission to level 2 (high dependency unit) or level 3
(intensive care unit) facilities,ii and/or death. Age was treated as
a categorical variable for univariate analyses. The lowest age
band (<1 year) was used as a reference for the comparison of the
two waves as the purpose was to compare distributions between
waves. However, for the analyses of severe outcome, the age
band of 16e24 years (least risk category) was used as the refer-
ence because we could not assume a linear relationship between
age and severe outcome. Continuous variables such as serum
C-reactive protein (CRP) levels were coded categorically to
facilitate clinical interpretation.8 9 A multivariable regression
analysis was conducted for statistically signiﬁcant variables
(p#0.05) identiﬁed during univariate analyses. Two separate
models were constructed to examine potential predictors of
severe outcome: model 1 included patient characteristics
(demographic characteristics and pre-existing comorbidities)
while model 2 included clinical characteristics (symptoms,
ﬁndings of clinical examination and investigations). Both models
were then restricted to include only the variables that were
signiﬁcantly associated with an increased risk, and receiver
operating characteristics (ROC) curves were plotted to explore
the prediction of severe outcome. In essence, the predictive
ability of the ﬁnal model for severe outcome was calculated by
assigning each patient an unweighted score of ‘1’ for every
risk factor present, and calculating sensitivity and speciﬁcity
for each cut-off value. All analyses were conducted using
Stata, V.11.
RESULTS
Overview
Data were obtained on 1520 patients with conﬁrmed pandemic
H1N1 infection. Illness onset occurred from 25 April 2009 to 26
January 2010 (online supplementary ﬁgure 1). The median
length of hospital stay was 3 days (IQR 2e6). One in six (16.5%)
patients needed admission to high dependency (4.1%) or inten-
sive care (12.4%) units (respectively level 2 and level 3 care) and
the in-hospital case death rate was 5.3% (children 0e15 years:
3.8%; adults 16e64 years: 5.6%; older people >65 years: 10.7%;
ﬁrst wave: 5.0%; second wave: 5.4%).
Patient characteristics
Table 1 summarises socio-demographic characteristics; the
median age was 26 years (IQR 9e44). There were higher
proportions of patients in age bands 0e4 (17%) and 16e34
(32%) compared with the general population. However,
compared with pre-pandemic hospital admissions for acute
respiratory infection (ARI) during the immediately preceding
inﬂuenza active winter period (November 2008eMarch 2009),
there was an inverse age distribution with fewer patients in age
bands 0e4 and $65 and substantially higher proportions in age
bands from 5 to 54. Among women, 20.8% were pregnant
compared with an estimated national prevalence of pregnancy
5.6% in the female population aged 15e44 years (table 2). There
was an over-representation of non-white ethnic groups in the
FLU-CIN cohort compared with the UK general population and
ARI admissions during the previous winter. More than half of all
Table 1 Demographic characteristics of 1520 UK patients hospitalised
with pandemic H1N1 infection during the 2009e2010 pandemic
compared with source population and pre-pandemic hospital data on
acute respiratory infection admissions
n (%)
UK population
comparison, %
Pre-pandemic hospital
data, acute respiratory
infections,* %
Sexy
Men 720 (47.4) 48.7 50.4
Women 800 (52.6) 51.3 49.6
Age (years)z
<1 121 (8.0) 1.3 14.7
1e4 138 (9.1) 4.8 12.6
5e15 221 (14.5) 12.6 4.8
16e24 245 (16.1) 12.1 2.5
25e34 242 (15.9) 12.9 3.3
35e44 195 (12.8) 14.6 4.6
45e54 168 (11.0) 13.5 5.4
55e64 115 (7.6) 11.8 7.9
65e74 55 (3.6) 8.5 11.0
>75 20 (1.3) 7.8 33.2
Ethnicityx
White 630 (41.5) 92.1 83.3
Mixed 11 (0.7) 1.2 1.9
Asian/Asian British 249 (16.4) 4.0 8.7
Black/black British 129 (8.5) 2.0 3.4
Chinese and other 121 (8.0) 0.8 2.7
*Hospital Episodes Statistics data: primary discharge codes relating to possible influenza
admissions (J06, J10, J11, J13-22) were considered for the pre-pandemic influenza active
period November 2008eMarch 2009.
yCensus 2001 data for comparison of sex (KS01 tables) were obtained from the Office for
National Statistics (ONS) (http://www.statistics.gov.uk).
zDemographic data on age distribution based on 2009 mid-year population estimates
(ONS).
xEthnicity data from ONS (Census 2001 data, 2001 data from the General Register Office
for Scotland and Northern Ireland Statistics and Research Agency).
Missing data for 380 (25%).
iChildren’s hospitals and tertiary respiratory referral centres were not mutually
exclusive; one of three extracorporeal membrane oxygenation centres was
a children’s hospital.
iiLevel 0: patients whose care needs can be met through normal ward care; level 1:
patients at risk of deteriorating or recently relocated from higher levels of care whose
needs can be met on an acute ward with additional advice and support from the
critical care team; level 2: patients requiring more detailed observation or
intervention, including support for a single failing organ system and those ‘stepping
down’ from higher levels of caredhigh dependency unit; level 3: patients requiring
advanced respiratory support alone or basic respiratory support together with
support of at least two organ systems. This includes all complex patients requiring
support for multi-organ failuredintensive care unit.
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admitted patients (55.1%) did not have any recorded pre-existing
comorbidity at the time of admission (table 2).
Preadmission care
The mean interval between symptom onset and admission to
hospital was 2 days (median 2 days; IQR 1e4). ‘Delayed admis-
sion’ was deﬁned as an interval of $5 days between symptom
onset and presentation at hospital.iii After excluding missing data
(n¼450), 227 of 1070 patients (21.2%) had a delayed admission.
Prior to admission, 417 of 1520 patients (27.4%) consulted
a general practitioner (GP) with inﬂuenza-like symptoms. Patients
who experienced delayed admission were not signiﬁcantly
different to ‘early’ admissions in relation to age (median 27.0 years
vs 25.0 years; p¼0.361) or number of comorbidities (median 0 vs
1; p¼0.023). However, radiological pneumonia (unadjusted OR
1.83; 95% CI 1.27 to 2.63) and severe outcome (unadjusted OR
1.67; 95% CI 1.15 to 2.43) were associated with delayed admis-
sion. Pre-admission GP consultation was signiﬁcantly associated
with delayed admission (unadjusted OR 2.09; 95% CI 1.41 to
3.11). Pre-admission antiviral drugs and antibiotics had been given
to 172 (11.3%) and 280 (18.4%) of the cohort, respectively. There
was no difference in pre-admission antiviral use between early and
delayed admissions (96 of 843 (11.4%) vs 25 of 227 (11.0%),
respectively) but a threefold increase in the likelihood of receiving
pre-admission antibiotics in patients with delayed admission (76
of 227 (33.4%) vs 118 of 843 (14.0%); unadjusted OR 3.09; 95% CI
2.21 to 4.33). Of the 87 patients (38.3%) with delayed admission
who had also seen a GP, 8 (9.2%) were prescribed antiviral drugs in
contrast to 50 (57.5%) prescribed antibiotics.
There were 987 cases admitted prior to 23 October 2009
who would not have had the opportunity to be vaccinated or to
have seroconverted (even if vaccinated) prior to illness onset.
In the remaining 533 patients, 2009 seasonal and pandemic
vaccination was recorded in only 21 and 12 instances,
respectively.
Clinical presentation and results of early investigations
The most common presenting symptoms upon admission in
adults and children are summarised in ﬁgure 1. Online supple-
mentary table 1 summarises vital signs on admission and early
investigations for the FLU-CIN cohort.
Pneumonia
There were 239 (15.7%) pneumonia cases on the basis of
radiological reports. A manual review of unreported chest x-ray
ﬁndings recorded in the case notes (by an unblinded respiratory
physician) found 15 additional cases that could be classiﬁed as
pneumonia based on documentation of acute pulmonary inﬁl-
trates and bilateral changes, giving a total of 254 (16.7%)
radiological pneumonia cases in the FLU-CIN cohort. The
median age of patients with pneumonia was 42 years (IQR
29e54) compared with 23 years (IQR 7e41) for non-pneumonia
patients (p<0.001). Of pneumonia cases, 27% had been
prescribed pre-admission antibiotics whereas only 13% had been
prescribed pre-admission antiviral drugs. From 2087 specimens
including 941 nose/throat swabs, 503 blood cultures, 234 urine,
70 stool and 195 sputum specimens taken, the following
bacteria were identiﬁed: Staphylococcus aureus (n¼7), Streptococcus
pneumoniae (n¼5), Escherichia coli (n¼5), Haemophilus inﬂuenzae
(n¼5), Pseudomonas aeruginosa (n¼2), Klebsiella spp. (n¼1),
coagulase-negative staphylococci (n¼1) and mixed bacterial ﬂora
(n¼11).
Differences by pandemic wave
These data are summarised in table 3. Signiﬁcantly lower pro-
portions of school-age children and young adults (age 5e24
Table 2 Pre-admission comorbidity in 1520 patients hospitalised with pandemic H1N1 infection during the 2009e2010 pandemic compared with
national prevalence data
Underlying medical conditions
Children (<16 years),
n[480 (31.6%), n (%)
Adults, n[1040
(68.4%), n (%)
All admissions,
(n[1520), n (%)
Background, prevalence
in the general population,* %
No. of comorbiditiesy
0 346 (72.1) 492 (47.3) 838 (55.1) e
1 115 (23.9) 394 (37.9) 509 (33.5) e
2 or more 19 (4.0) 154 (14.8) 173 (11.4) e
Comorbidity
Cardiovascular disease 20 (4.2) 168 (16.2) 188 (12.4) 3.5
Pulmonary disease
COPD 0 (0.0) 83 (8.0) 83 (5.5) 1.5
Asthma 71 (14.8) 314 (30.2) 385 (25.3) 5.9
Other pulmonary disease 16 (3.3) 20 (2.0) 36 (2.4) e
Diabetes 6 (1.3) 96 (9.2) 102 (6.7) 4.1
Other metabolic disease 8 (1.7) 4 (0.4) 12 (0.8) e
Neurological disease 36 (7.5) 51 (5.0) 87 (5.7) e
Cerebrovascular disease 0 (0.0) 5 (0.5) 5 (0.5) 1.7
Obesity recorded on admissiony 3 (0.6) 46 (4.4) 49 (3.2) 8.1z
Pregnancy 1 82 (20.3)x 83 (20.8)x 5.6{
*National prevalence data on comorbidity were obtained from the Quality and Outcomes Framework (QOF) primary care data for 2009 (http://www.qof.ic.nhs.uk) and are based on all ages,
except for pregnancy.
yRecorded obesity and pregnancy are excluded from the number of comorbidities in the upper part of table 2.
zNational prevalence data on obesity based on QOF obesity registers, defined as body mass index $30.
xPercentage of pregnancies shown represents proportion in women aged 16e44.
{5.6% of women aged 15e44 estimated to be pregnant in source population: in addition to 761 934 live births in the UK in 2008 (Office of National Statistics, General Register Office for
Scotland and Northern Ireland Statistics and Research Agency) we assumed that 4% of women aged 15e44 years experienced a miscarriage or abortion in the same time period (500 084). To
calculate the prevalence of pregnancy we took 9/12 of annual live births (assuming 9-month duration of pregnancy) and 3/12 of miscarriages/abortions (assuming 3-month duration), divided by
the total female population aged 15e44 years (12 502 100).
iiiThe term ‘delayed admission’ defines the interval between symptom onset and
admission as $5 days, but does not carry any imputation that the delay in all cases
was undesirable or clinically suboptimal.
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years) were admitted during the second wave, and the propor-
tion of people from non-white ethnic groups also declined
signiﬁcantly (becoming similar to that seen during seasonal
inﬂuenza activity). But higher proportions of patients presented
with dyspnoea, altered consciousness and CRP levels $31 mg/
litre. Hospital stays <2 days’ duration were 33% less likely in the
second wave (unadjusted OR 0.67; 95% CI 0.52 to 0.88), but the
likelihoods of delayed admission (unadjusted OR 1.93; 95% CI
1.42 to 2.63), and needing level 2/3 care (unadjusted OR 1.76;
95% CI 1.31 to 2.37) were both higher, although there were no
apparent differences in mortality. The frequency of prescribing
of pre-hospital antiviral drugs decreased from 13.3% to 10.0%
between the ﬁrst and second waves, respectively (p¼0.048),
whereas the use of pre-hospital antibiotics increased from 13.6%
to 21.6% (p<0.001).
Factors associated with severe outcome
Univariate analysis
The risk of severe outcome varied by age band and was generally
highest in the youngest children (age <1 year) and those aged
45 years and over (table 4). However, a further sensitivity anal-
ysis using quinquennial age bands showed an increased risk in
children under 1 year, those aged 31e40 and older adults (age
>50 years), following a W-shaped distribution (ﬁgure 2). An
increased risk of severe outcome was associated with speciﬁc
comorbidities (pre-existing chronic lung disease (excluding
asthma and chronic obstructive pulmonary disease (COPD)),
neurological disorders and cardiovascular disease); but there was
no relation to total comorbidity burden. Recorded obesity was
also associated with increased risk. In contrast, pre-existing
asthma was associated with signiﬁcantly decreased risk of severe
outcome. No signiﬁcant association was observed between
pregnancy and severe outcome (unadjusted OR 0.92; 95% CI
0.47 to 1.83).iv
Dyspnoea, altered consciousness, levels of CRP $100 mg/litre,
need for supplemental oxygen or intravenous ﬂuid replacement
on admission were all associated with an increased risk of severe
outcome, as was the use of pre-admission antibiotics. Radio-
logically conﬁrmed pneumonia was strongly associated with
severe outcome.
Demographic and comorbid independent predictors of severe
outcome
Model 1 considered patient characteristics (socio-demographic
and comorbidities) that could predict severe outcome: age,
asthma, cardiovascular disease, chronic lung disease (non-
asthma, non-COPD) and neurological disorders (table 5). We
observed statistically signiﬁcant increased risks associated
with the age band 55e64 years (adjusted OR 2.08; 95% CI
1.16 to 3.74), pre-existing lung disease (excluding asthma and
COPD) (adjusted OR 2.40; 95% CI 1.17 to 4.93), neurological
disorders (adjusted OR 2.59; 95% CI 1.62 to 4.15) and recorded
obesity (adjusted OR 2.22; 95% CI 1.18 to 4.18). Pre-existing
asthma was associated with reduced likelihood of severe
outcome (adjusted OR 0.49; 95% CI 0.34 to 0.70). In view of the
complex, nonlinear relationship between age and severe
outcome, model 1 was also analysed excluding age, with similar
ﬁndings (online supplementary table 2).
Clinical parameters independently predictive of severe outcome
Model 2 included delayed admission because this had a signiﬁ-
cant effect on severe outcomes in the univariate analysis
(table 6). Radiologically conﬁrmed pneumonia (adjusted OR
1.83; 95% CI 1.27 to 2.64), delayed admission (adjusted OR 1.67;
95% CI 1.09 to 2.56), altered consciousness on presentation
(adjusted OR 6.53; 95% CI 3.73 to 11.41) and CRP levels
$100 mg/litre (adjusted OR 3.78; 95% CI 2.41 to 5.94) were
independently associated with severe outcomes as was a need
for supplemental oxygen or intravenous ﬂuid replacement on
admission (adjusted OR 4.34; 95% CI 3.09 to 6.08; and adjusted
OR 1.86; 95% CI 1.30 to 2.66, respectively). Figure 3 shows the
ROC curves and area under curve values for the two resulting
models with only the independent predictors of increased risk.
In the case of model 1 a new variable representing the age group
55e64 years was created to construct the ROC curve, to allow
for the nonlinear increase in risk observed with age.
DISCUSSION
Although limited to severe inﬂuenza cases requiring hospital-
isation, these data provide important information on predictors
of severe outcomes and the impact of clinical management.
They also suggest potential for improvement in the community
management of pandemic inﬂuenza that might inﬂuence disease
progression. Hospitals were asked to notify all cases with
Figure 1 Frequency of presenting
symptoms in adults and children
(<16 years) hospitalised with
pandemic H1N1 infection during the
2009e2010 pandemic.
ivComparator restricted to non-pregnant women aged 16e44 years in the FLU-CIN
cohort.
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Table 3 Comparative analysis of comorbidity, demography, clinical characteristics and selected investigations in first wave versus second wave for
patients hospitalised with pandemic H1N1 infection during the 2009e2010 pandemic (n¼1520)
Patient characteristic
First wave,
n[601 (39.5%), n (%)
Second wave,
n[919 (60.5%), n (%)
Unadjusted OR*
(95% CI)
Age-adjusted
OR (95% CI)
Age (years)
<1 39 (6.5) 82 (8.9) 1.00 (reference) e
1e4 60 (10.0) 78 (8.5) 0.62 (0.37 to 1.03)
5e15 116 (19.3) 105 (11.4) 0.43 (0.27 to 0.68)
16e24 106 (17.6) 139 (15.1) 0.62 (0.39 to 0.99)
25e34 87 (14.5) 155 (16.9) 0.85 (0.53 to 1.35)
35e44 72 (12.0) 123 (13.4) 0.81 (0.50 to 1.31)
45e54 59 (9.8) 109 (11.9) 0.88 (0.54 to 1.44)
55e64 33 (5.5) 82 (8.9) 1.18 (0.68 to 2.06)
$65 29 (4.8) 46 (5.0) 0.75 (0.41 to 1.38)
p Value p trend¼0.010
Ethnicity
White 180 (30.0) 450 (49.0) 1.00 1.00
Other 337 (56.1) 173 (18.8) 0.21 (0.16 to 0.26) 0.21 (0.16 to 0.27)
Missing 84 (14.0) 296 (32.2) e e
p Value <0.001 <0.001
Neurological disorders 45 (7.5) 42 (4.6) 0.59 (0.38 to 0.91) 0.60 (0.39 to 0.92)
p Value 0.018 0.020
Radiological pneumonia 79 (13.1) 175 (19.0) 1.55 (1.16 to 2.07) 1.41 (1.04 to 1.90)
p Value 0.003 0.025
C-reactive protein (mg/litre)
#30 171 (28.5) 222 (24.2) 1.00 1.00
31e99 91 (15.1) 171 (18.6) 1.45 (1.05 to 2.00) 1.39 (0.99 to 1.93)
100 40 (6.7) 122 (13.3) 2.35 (1.56 to 3.54) 2.22 (1.46 to 3.39)
Missing 299 (49.8) 404 (44.0) e e
p Value p trend <0.001 P trend <0.001
Altered consciousness 21 (3.5) 53 (5.8) 1.69 (1.01 to 2.83) 1.72 (1.03 to 2.89)
p Value 0.046 0.040
Dyspnoea 191 (31.8) 384 (41.8) 1.54 (1.24 to 1.91) 1.46 (1.17 to 1.82)
p Value <0.001 0.001
Pre-admission antibiotics 82 (13.6) 198 (21.6) 1.74 (1.31 to 2.30) 1.69 (1.27 to 2.24)
p Value <0.001 <0.001
Pre-admission antiviral drugs 80 (13.3) 92 (10.0) 0.72 (0.53 to 0.99) 0.73 (0.53 to 1.00)
p Value 0.048 0.049
Delayed admission
No 420 (69.9) 423 (46.0) 1.00 1.00
Yes 77 (12.8) 150 (16.3) 1.93 (1.42 to 2.63) 1.91 (1.41 to 2.60)
Missing 104 (17.3) 346 (37.6) e e
p Value <0.001 <0.001
Required supplemental oxygen on admission 154 (25.6) 281 (30.6) 1.28 (1.02 to 1.61) 1.21 (0.96 to 1.53)
p Value 0.037 0.104
Intravenous fluid replacement on admission 179 (29.8) 211 (23.0) 0.70 (0.56 to 0.89) 0.70 (0.55 to 0.88)
p Value 0.003 0.002
Oxygen saturation <94% on air
No 61 (10.2) 315 (34.3) 1.00 1.00
Yes 178 (29.6) 439 (47.8) 0.48 (0.35 to 0.66) 0.49 (0.35 to 0.68)
Missing 362 (60.2) 165 (18.0) e e
p Value <0.001 <0.001
Length of hospital stay
<2 days 137 (22.8) 152 (16.5) 1.00 1.00
$2 days 395 (65.7) 650 (70.7) 1.48 (1.14 to 1.93) 1.41 (1.08 to 1.84)
Missing 69 (11.5) 117 (12.7) e e
p Value 0.003 0.012
Adverse outcomes (death or level 2 or 3 admission) 80 (13.3) 188 (20.5) 1.67 (1.26 to 2.23) 1.64 (1.23 to 2.18)
p Value <0.001 0.001
Level 2 or 3 admission 72 (12.0) 178 (19.4) 1.76 (1.31 to 2.37) 1.73 (1.29 to 2.33)
p Value <0.001 <0.001
*All comparisons are second wave compared with first wave.
No statistically significant differences were found by pandemic wave in the following patient characteristics: sex; comorbidities such as asthma, chronic obstructive pulmonary disease (COPD)
and chronic pulmonary conditions other than asthma or COPD; hepatic disease, cardiovascular disease, diabetes, hypertension, immunocompromised status, or total comorbidity burden;
recorded obesity, smoking status, pregnancy; inpatient treatment with antivirals or antibiotics; and mortality.
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conﬁrmed pandemic H1N1 and cases were followed up without
selection. Nevertheless, the inclusion of several children’s
hospitals and tertiary respiratory referral centres may alter the
representativeness of our ﬁndings and case ascertainment may
not have been complete in all centres.
Our analysis identiﬁed that only 11% of the FLU-CIN cohort
had been prescribed pre-admission antiviral drugs despite
a national policy for making them widely available.10 The
signiﬁcant decline in use of antiviral drugs between ﬁrst and
second waves (despite the opening of the National Pandemic Flu
Service in late July 2009)10 and the concomitant increase in the
frequency of antibiotic use suggest that GPs may have reverted
to the use of antibiotics rather than antivirals during the second
wave. However, very few (<3%) bacterial infections were
conﬁrmed in the cohort. These data also imply that affordable,
speciﬁc and sensitive near-patient tests for inﬂuenza could, in
future, offer a signiﬁcant advance to inﬂuenza management
strategies by informing the appropriate use of antiviral drugs.
One in ﬁve admissions were delayed and such patients were
more likely to suffer a severe outcome, as reported elsewhere.11
Patients with delayed admission were not different in terms of
age or comorbidities. However, without access to primary care
data, we cannot determine whether such patients could have
been identiﬁed for earlier admission or treatment.
The age bands 0e4 and 16e34 years were markedly over-
represented in the FLU-CIN cohort compared with the UK
general population. However, in comparison to winter seasonal
admissions for ARI, the age bands from 5 to 54 years were over-
represented. There was also an over-representation of non-white
ethnic groups compared with the source population and in
relation to ARI admissions during seasonal inﬂuenza activity
(ﬁrst wave only), but no differences in progression to severe
outcome were noted. The association between severe outcome
and age was nonlinear, with infants <1 year and the over
50s showing an increased risk. Moreover, ﬁgure 2 describes
a W-shaped distribution, as seen in the severe pandemic of
1918,12 and in Canada and the Netherlands in 2009.13 14 This
phenomenon may be related to antigenic similarity between
1918-like and 2009 viruses,15 and immune complex-mediated
disease in some middle-aged adults.16
Over half of patients had no pre-existing comorbidity and
about 41% of in-hospital deaths occurred in those who were
Table 4 Analysis of comorbidity, demography, clinical characteristics, care pathway and selected investigations as risk factors for severe
outcomes (level 2 or 3 admission and/or death) in patients hospitalised with pandemic H1N1 infection during the 2009e2010 pandemic
(n¼1520)
Patient characteristic
Cases (severe outcomes),
n[268 (17.6%), n (%)
Controls, n[1252
(82.4%), n (%)
Unadjusted OR
(95% CI) p Value
Age (years)
<1 25 (9.3) 96 (7.7) 1.87 (1.04 to 3.34) 0.036
1e4 23 (8.6) 115 (9.2) 1.43 (0.80 to 2.58) 0.231
5e15 29 (10.8) 192 (15.3) 1.08 (0.63 to 1.87) 0.776
16e24 30 (11.2) 215 (17.2) 1.00 (reference) e
25e34 44 (16.4) 198 (15.8) 1.59 (0.96 to 2.63) 0.070
35e44 37 (13.8) 158 (12.6) 1.68 (0.99 to 2.83) 0.053
45e54 33 (12.3) 135 (10.8) 1.75 (1.02 to 3.00) 0.042
55e64 30 (11.2) 85 (6.8) 2.53 (1.44 to 4.45) 0.001
$65 17 (6.3) 58 (4.6) 2.10 (1.08 to 4.07) 0.028
Asthma 43 (16.0) 342 (27.3) 0.51 (0.36 to 0.72) <0.001
Chronic pulmonary conditions excluding asthma or COPD 12 (4.5) 24 (1.9) 2.40 (1.18 to 4.86) 0.015
Neurological disorders 31 (11.6) 56 (4.5) 2.79 (1.76 to 4.43) <0.001
Cardiovascular disease 50 (18.7) 138 (11.0) 1.85 (1.30 to 2.64) 0.001
Radiological Pneumonia 94 (35.1) 160 (12.8) 3.69 (2.73 to 4.98) <0.001
C-reactive protein (mg/litre)
#30 38 (14.2) 355 (28.4) 1.00
31e99 41 (15.3) 221 (17.7) 1.73 (1.08 to 2.78) 0.022
$100 73 (27.2) 89 (7.1) 7.66 (4.86 to 12.09) <0.001
Missing 116 (43.3) 587 (46.9) e
Recorded obese 17 (6.3) 32 (2.6) 2.58 (1.41 to 4.72) 0.002
Altered consciousness 40 (14.9) 34 (2.7) 6.28 (3.89 to 10.14) <0.001
Dyspnoea 141 (52.7) 434 (34.7) 2.09 (1.60 to 2.73) <0.001
Pre-admission antibiotics 74 (27.6) 206 (16.5) 1.94 (1.43 to 2.63) <0.001
Required supplemental oxygen on admission 163 (60.8) 272 (21.7) 5.59 (4.23 to 7.40) <0.001
Intravenous fluid replacement on admission 93 (34.7) 297 (23.7) 1.71 (1.29 to 2.27) <0.001
Delayed admission
No 114 (42.5) 729 (58.2) 1.00
Yes 47 (17.5) 180 (14.4) 1.67 (1.15 to 2.43) 0.008
Missing 107 (39.9) 343 (27.4) e
Length of hospital stay
<2 days 5 (1.9) 284 (22.7) 1.00
$2 days 170 (63.4) 875 (69.9) 11.04 (4.49 to 27.12) <0.001
Missing 93 (34.7) 93 (7.4) e
In-hospital antibiotic therapy 235 (87.7) 1020 (81.5) 1.62 (1.10 to 2.40) 0.016
No statistically significant association was observed between severe outcomes (level 2 or 3 admission or death) and the following patient characteristics: sex, ethnicity; comorbidities such as
chronic obstructive pulmonary disease (COPD), hepatic disease, diabetes, hypertension, immunocompromised status or total comorbidity burden; smoking status, pregnancy, pre-admission
antiviral use, oxygen saturation <94% on air; and inpatient treatment with antivirals.
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previously healthy. People with pre-existing neurological disease
and chronic pulmonary disease (other than asthma or COPD),
and those with physician-deﬁned obesity were at increased risk
of severe outcomes as observed worldwide.17e23 Although 65%
of patients recorded as obese had one or more underlying
comorbidities, after adjustment, this remained an independent
risk factor, possibly explained by respiratory compromise or
a pro-inﬂammatory state.24 25
The most common comorbidity was asthma, which was
associated with a decreased risk of severe outcome and is
consistent with other reports.17 18 22 Possible explanations
include a lower threshold for admission26 or earlier admission
(patients with asthma were signiﬁcantly less likely to have
a delayed admission compared with those without asthma;
unadjusted OR 0.68, 95% CI 0.48 to 0.96). Lastly, it is
possible that corticosteroid administration as part of asthma
management protected patients with asthma from severe
outcomes. These hypotheses are discussed in more detail in
a subsequent manuscript.
All of the following were independent predictors of severe
outcome: altered consciousness, need for supplemental
oxygen or intravenous ﬂuid replacement at admission, CRP
$100 mg/litre and inﬂuenza-related pneumonia, as noted
elsewhere.17 18 23 27
Comparing pandemic waves, we found a 33% decreased like-
lihood of a length of stay <2 days, higher proportions of dysp-
noea, altered consciousness and raised CRP; and a higher
likelihood of delayed admission and of needing level 2 or 3 care,
but lower levels of pre-admission antiviral use in the second
wave. Together, these data may reﬂect greater conﬁdence among
GPs and receiving physicians to manage milder cases at home,
and a lower perceived beneﬁt from antiviral drugs for milder
cases. In addition, in-hospital mortality appeared unchanged
between waves and we found no statistically signiﬁcant differ-
ences in the factors inﬂuencing severe outcomes by wave.
However, other work suggests that case death rate increased
from 0.015% to 0.025% between the ﬁrst and second waves in
the UK.28
Figure 2 Unadjusted OR of severe
outcome by age (OR and 95% CI) for
patients hospitalised with pandemic
H1N1 infection during the 2009e2010
pandemic. Severe outcome defined as
admission to high dependency (level 2)
or intensive (level 3) care facilities,
and/or death.
Table 5 Multivariable analysis: Patient characteristics independently
predictive of severe outcomes in pandemic influenza during the
2009e2010 pandemic (n¼1520)
Patient characteristic Adjusted* OR (95% CI) p Value
Socio-demographic characteristics
Age (years)
<1 1.60 (0.88 to 2.90) 0.123
1e4 1.20 (0.66 to 2.19) 0.545
5e15 0.91 (0.52 to 1.59) 0.740
16e24 1.00 (reference) e
25e34 1.60 (0.96 to 2.66) 0.071
35e44 1.47 (0.86 to 2.52) 0.164
45e54 1.46 (0.84 to 2.56) 0.183
55e64 2.08 (1.16 to 3.74) 0.014
$65 1.45 (0.71 to 2.93) 0.308
Underlying comorbidities
Asthma 0.49 (0.34 to 0.70) <0.001
Cardiovascular disease 1.43 (0.96 to 2.13) 0.075
Other lung disease excluding
COPD and asthma
2.40 (1.17 to 4.93) 0.018
Neurological disorders 2.59 (1.62 to 4.15) <0.001
Recorded obesity 2.22 (1.18 to 4.18) 0.013
*Each variable has been adjusted for all other variables in the model.
COPD, chronic obstructive pulmonary disease.
Table 6 Multivariable analysis: clinical parameters independently
predictive of severe outcomes in pandemic influenza during the
2009e2010 pandemic (n¼1520)
Clinical parameter Adjusted* OR (95% CI) p Value
Delayed admission 1.67 (1.09 to 2.56) 0.019
Radiologically confirmed pneumonia 1.83 (1.27 to 2.64) 0.001
Presenting symptoms
Dyspnoea 1.22 (0.88 to 1.67) 0.231
Altered consciousness 6.53 (3.73 to 11.41) <0.001
Required supplemental oxygen
on admission
4.34 (3.09 to 6.08) <0.001
Intravenous fluid replacement
on admission
1.86 (1.30 to 2.66) 0.001
Clinical parameters
C-reactive protein (mg/dl)
($100 vs <100)
3.78 (2.41 to 5.94) <0.001
*Each variable has been adjusted for all other variables in the model.
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Data from the ROC analysis suggest that patient character-
istics in model 1 (age 55e64 years, lung disease other than
asthma or COPD, neurological disorders, recorded obesity) were
not good predictors of severe outcomes (ROC area under the
curve 0.65). This was probably because the combination of these
variables is too rare to serve as a generic prediction rule.
However, the clinical parameters in model 2 proved better
predictors of severe outcomes with a ROC area under the curve
value of 0.80 (delayed admission, pneumonia, altered
consciousness, the need for supplemental oxygen or intravenous
ﬂuid on admission, CRP levels $100 mg/litre). It is, of course,
arguable whether any model based on hospital observations has
any use unless earlier intervention would be possible. However,
patients with markers of potential severity on admission could
be earmarked for early review by specialised respiratory physi-
cians and intensivists. The next step would be to conduct
a formal, prospective, head-to-head comparison of our algorithm
with other triage tools.29
CONCLUSIONS
During the H1N1 pandemic in the UK in 2009e2010, among
hospitalised patients, independent predictors of severe outcomes
were increasing age, pre-existing chronic lung disease (excluding
asthma or COPD), neurological disease and recorded obesity, but
asthma was associated with decreased risk. Additional indepen-
dent predictors of severe outcome were delayed admission, dysp-
noea, radiographical pneumonia, altered consciousness, need for
supplemental oxygen or intravenous ﬂuid replacement on admis-
sion and CRP levels $100 mg/litre. The age-related risk of severe
outcome followed a W-shaped distribution similar to that
described for mortality in the 1918e1919 pandemic. An increase in
the proportion of non-white patients compared with ARI admis-
sions during seasonal inﬂuenza activity, seen in the ﬁrst pandemic
wave, was not maintained during the second wave. In-patient
mortality rates were unchanged between waves but the threshold
for admission probably increased during the second wave.
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